Vancouver, British Columbia – (August 19th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study” will be on cover of Cancers. Rashid Ahmed, President and CEO, says, “This latest paper […]
© 2021 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.